Ethambutol
Myambutol (ethambutol) is a small molecule pharmaceutical. Ethambutol was first approved as Myambutol on 1982-01-01. It is used to treat mycobacterium infections, nontuberculous mycobacterium infections, and tuberculosis in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Myambutol (generic drugs available since 1999-11-30)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethambutol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MYAMBUTOL | STI Pharma | N-016320 RX | 1982-01-01 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ethambutol hydrochloride | ANDA | 2023-03-30 |
| myambutol | New Drug Application | 2022-02-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycobacterium infections | — | D009164 | A31.9 |
| nontuberculous mycobacterium infections | EFO_0007461 | D009165 | A31.9 |
| tuberculosis | EFO_0000774 | D014376 | A15-A19 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AK: Other drugs for treatment of tuberculosis in atc
— J04AK02: Ethambutol
— J04AM: Combinations of drugs for treatment of tuberculosis
— J04AM03: Ethambutol and isoniazid
— J04AM06: Rifampicin, pyrazinamide, ethambutol and isoniazid
— J04AM07: Rifampicin, ethambutol and isoniazid
HCPCS
No data
Clinical
Clinical Trials
74 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 2 | 9 | 9 | 2 | 4 | 25 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 7 | 7 | 3 | 4 | 21 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 9 | 6 | 1 | 4 | 19 |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | 5 | 3 | 1 | 1 | 10 | |
| Nontuberculous mycobacterium infections | D009165 | EFO_0007461 | A31.9 | — | 1 | 3 | 1 | — | 4 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | 2 | — | 3 |
| Spinal tuberculosis | D014399 | A18.01 | — | — | — | 1 | — | 1 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | O98.7 | — | 2 | 2 | — | — | 4 | |
| Mycobacterium avium complex | D015269 | — | 1 | 2 | — | — | 2 | ||
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | 1 | 2 | — | — | 2 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 2 | — | — | 2 | |
| Anterior uveitis | D014606 | EFO_1000811 | — | — | 1 | — | — | 1 | |
| Extensively drug-resistant tuberculosis | D054908 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoidosis | D012507 | EFO_0000690 | D80-D89 | — | 1 | — | — | — | 1 |
| Meningeal tuberculosis | D014390 | A17.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary sarcoidosis | D017565 | DOID_13406 | D86.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | 1 | 1 | ||
| Motor activity | D009043 | EFO_0003940 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ETHAMBUTOL |
| INN | ethambutol |
| Description | Ethambutol is an ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone. It has a role as an antitubercular agent, an environmental contaminant and a xenobiotic. It is a member of ethanolamines and an ethylenediamine derivative. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@@H](CO)NCCN[C@@H](CC)CO |
Identifiers
| PDB | — |
| CAS-ID | 74-55-5 |
| RxCUI | 4110 |
| ChEMBL ID | CHEMBL44884 |
| ChEBI ID | 4877 |
| PubChem CID | 14052 |
| DrugBank | DB00330 |
| UNII ID | 8G167061QZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,905 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more